Table 1.
COVID-19 vaccines that are in phase 3 or 4 of clinical trials, based on WHO report on July 6, 2021 [56].
| Developer | Platform | Clinical trial phase | Number of doses | Dose schedule in healthy cases (day) | Study report | |
|---|---|---|---|---|---|---|
| 1 | Sinovac Research and Development Co., Ltd | Inactivated virus | 4 | 2 | 0, 14 | [57], [59] |
| 2 | Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products | Inactivated virus | 3 | 2 | 0, 21 | – |
| 3 | Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products | Inactivated virus | 4 | 2 | 0, 21 | – |
| 4 | Institute of Medical Biology + Chinese Academy of Medical Sciences | Inactivated virus | 3 | 2 | 0, 28 | [61] |
| 5 | Research Institute for Biological Safety Problems, Rep of Kazakhstan | Inactivated virus | 3 | 2 | 0, 21 | – |
| 6 | Bharat Biotech International Limited | Inactivated virus | 3 | 2 | 0, 14 | [62] |
| 7 | Shifa Pharmed Industrial Co | Inactivated virus | 2/3 | 2 | 0, 14 | – |
| 8 | Shenzhen Kangtai Biological Products Co., Ltd. | Inactivated virus | 3 | 2 | 0, 28 | – |
| 9 | Valneva. National Institute for Health Research. | Inactivated virus | 3 | 2 | 0, 21 | – |
| 10 | Erciyes University, Turkey | Inactivated virus | 3 | 2 | 0, 21 | – |
| 11 | AstraZeneca + University of Oxford | Viral vector (Non-replicating) | 4 | 1–2 | 0, 28 | [7], [45] |
| 12 | CanSino Biological Inc./ Beijing Institute of Biotechnology | Viral vector (Non-replicating) | 4 | 1 | 0 | [64] |
| 13 | Gamaleya Research Institute; Health Ministry of the Russian Federation | Viral vector (Non-replicating) | 3 | 2 | 0, 21 | [8] |
| 14 | Janssen Pharmaceuticals | Viral vector (Non-replicating) | 4 | 1–2 | 0 or 0, 56 | [65] |
| 15 | ReiThera + Leukocare + Univercells | Viral vector (Non-replicating) | 2/3 | 1 | 0 | – |
| 16 | Medicago Inc. | Virus like particle (VLP) | 2/3 | 2 | 0, 21 | [66] |
| 17 | Novavax | Protein subunit | 3 | 2 | 0, 21 | [67] |
| 18 | Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Protein subunit | 3 | 2–3 | 0, 28 or 0, 28, 56 | [68] |
| 19 | Clover Biopharmaceuticals Inc./GSK/Dynavax | Protein subunit | 2/3 | 2 | 0, 21 | – |
| 20 | Sanofi Pasteur + GSK | Protein subunit | 3 | 2 | 0, 21 | – |
| 21 | EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) | Protein subunit | 3 | 2 | 0, 21 | – |
| 22 | Instituto Finlay de Vacunas | Protein subunit | 3 | 2 | 0, 28 | – |
| 21 | Center for Genetic Engineering and Biotechnology (CIGB) | Protein subunit | 3 | 3 | 0, 14, 28 or 0, 28, 56 | – |
| 23 | Vaxxinity | Protein subunit | 2/3 | 2 | 0, 28 | – |
| 24 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector” | Protein subunit | 3 | 2 | 0, 21 | – |
| 25 | West China Hospital + Sichuan University | Protein subunit | 3 | 2 | 0, 28 | – |
| 26 | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd | DNA based vaccine | 2/3 | 2 | 0, 28 | [69] |
| 27 | AnGes + Takara Bio + Osaka University | DNA based vaccine | 2/3 | 2 | 0, 14 | – |
| 28 | Zydus Cadila | DNA based vaccine | 3 | 3 | 0, 28, 56 | – |
| 29 | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | RNA based vaccine | 4 | 2 | 0, 28 | [70] |
| 30 | Pfizer/BioNTech + Fosun Pharma | RNA based vaccine | 4 | 2 | 0, 21 | [53], [71] |
| 31 | CureVac AG | RNA based vaccine | 3 | 2 | 0, 28 | – |
| 32 | Academy of Military Sciences (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | RNA based vaccine | 3 | 2 | 0, 14 or 0, 28 | – |
| 33 | Moderna TX. Inc. | RNA based vaccine | 2/3 | 3 | 0, 21, 35 | – |